Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Dual use of E-cadherin and D2-40 immunostaining in unusual meningioma subtypes. Am J Clin Pathol 2015 Dec;144(6):923-34



Pubmed ID




Scopus ID

2-s2.0-84947983102 (requires institutional sign-in at Scopus site)   4 Citations


OBJECTIVES: Meningiomas usually can be readily diagnosed on H&E alone, although occasionally immunohistochemistry (IHC) confirmation is desirable. Studies exploring the diagnostic utility of either podoplanin (D2-40) or E-cadherin IHC in meningiomas have conflicted, and no studies exist in which the two IHCs have been used in combination for diagnosis.

METHODS: E-cadherin and D2-40 IHC was performed on 77 meningiomas (31 ordinary; eight microcystic; four rare myxoid; six metaplastic; six invasive of orbit, muscle, and/or soft tissue; two metastatic; six brain-invasive World Health Organization [WHO] grade II, nine non-brain-invasive WHO grade II; and five anaplastic WHO grade III), with semi-quantitative scoring on a three-tier scale (0, focal [1+], strong/diffuse [2+]).

RESULTS: All meningiomas were either E-cadherin or D2-40 IHC+, with 69 of 77 showing dual immunostaining, most at the 2+ level. No downregulation of E-cadherin IHC was found in invasive or high-grade meningiomas.

CONCLUSIONS: Dual E-cadherin/D2-40 IHC can supplement diagnosis of meningioma.

Author List

Mrachek EK, Davis D, Kleinschmidt-DeMasters BK


Edward Kelly S. Mrachek MD Assistant Professor in the Pathology department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Antibodies, Monoclonal, Murine-Derived
Biomarkers, Tumor
Meningeal Neoplasms
Retrospective Studies